{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Due to AE while on treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Due to PD during 30-day FU"}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"}],"units":"Participants"}],"description":"Presented are the number of participants who died due to adverse events (AEs) while on treatment and participants who died due to progressive disease (PD) during the 30-day post-treatment discontinuation FU.","groups":[{"description":"Cetuximab loading dose of 400 mg/m² administered intravenously on Day 1 of Cycle 1; subsequently 250 mg/m² administered intravenously weekly.\n\nPemetrexed 500 mg/m² administered intravenously on Day 1 of every 21-day cycle, 1 hour after cetuximab.\n\nCarboplatin AUC 5 or cisplatin 75 mg/m² administered intravenously on Day 1 of every 21-day cycle, 30 minutes after pemetrexed.\n\nMaximum 6 cycles. Participants who did not experience disease progression after 6 cycles continued on cetuximab (250 mg/m² intravenously weekly) monotherapy until disease progression.","id":"OG000","title":"Cetuximab + Pemetrexed + Carboplatin/Cisplatin"}],"paramType":"NUMBER","populationDescription":"All enrolled participants who received at least 1 dose of any study drug.","reportingStatus":"POSTED","timeFrame":"From enrollment to 30 days post-treatment discontinuation up to 26.4 months","title":"Number of Participants Who Died While on Treatment and Died During 30-Day Post-Treatment Discontinuation Follow-Up (FU)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"participants"}